A Phase 1 interventional study of LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study will last up to 49 days excluding the screening period.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Titration Period: Participants received increasing doses of LY3502970 administered orally every 7 days on Day 1 to Day 21. Day 1 to Day 8: 2 milligram (mg) LY3502970 every day (QD), Day 8 to Day 15: 4 mg LY3502970 QD, Day 15 to Day 21: 8 mg LY3502970 QD, Participants were randomized to Fasted state or Fed state sequence on Day 22.
Drug: LY3502970
Test Period 1: Participants received 16 mg LY3502970 administered orally QD, Day 22 to Day 28 in Fasted state. Test Period 2: Participants received 16 mg LY3502970 administered orally QD, Day 29 to Day 35 in Fed state.
Drug: LY3502970
Test Period 1: Participants received 16 mg LY3502970 administered orally QD, Day 22 to Day 28 in Fed state. Test Period 2: Participants received 16 mg LY3502970 administered orally QD, Day 29 to Day 35 in Fasted state.
Drug: LY3502970
Administered Orally.
PK: Maximum Observed Concentration (Cmax) of LY3502970
PK: Cmax of LY3502970.
Time frame: PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)
PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY3502970
PK: AUC0-24 of LY3502970.
Time frame: PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)
Time to Maximum Observed Concentration (Tmax) of LY3502970
PK: Tmax of LY3502970
Time frame: PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)
During the titration period, participants received increasing doses of LY3502970 administered orally every 7 days on Day 1 to Day 21. Upon completion of the titration period, participants were randomized to Fasted state or Fed state sequence of Day 22.
| Milestone | 2 Milligram (mg)/4 mg/8 mg LY3502970 | 16 mg LY3502970 (Fasted/Fed) | 16 mg LY3502970 (Fed/Fasted) |
|---|---|---|---|
| Started | 34 | 0 | 0 |
| Received at least one dose of study drug | 33 | 0 | 0 |
| Completed | 29 | 0 | 0 |
| Not completed | 5 | 0 | 0 |
| Withdrew: Adverse event | 5 | 0 | 0 |
| Milestone | 2 Milligram (mg)/4 mg/8 mg LY3502970 | 16 mg LY3502970 (Fasted/Fed) | 16 mg LY3502970 (Fed/Fasted) |
|---|---|---|---|
| Started | 0 | 15 | 14 |
| Received at least one dose of study drug | 0 | 15 | 14 |
| Completed | 0 | 13 | 13 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Milestone | 2 Milligram (mg)/4 mg/8 mg LY3502970 | 16 mg LY3502970 (Fasted/Fed) | 16 mg LY3502970 (Fed/Fasted) |
|---|---|---|---|
| Started | 0 | 13 | 13 |
| Received at least one dose of study drug | 0 | 13 | 13 |
| Completed | 0 | 13 | 13 |
| Not completed | 0 | 0 | 0 |
PK: Cmax of LY3502970.
| nanograms per milliliter (ng/mL) | 16 mg LY3502970 (Fasted) | 16 mg LY3502970 (Fed) |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of LY3502970 | 80.5 ± 64 | 67.5 ± 40 |
PK: AUC0-24 of LY3502970.
| ng*hour(h)/mL | 16 mg LY3502970 (Fasted) | 16 mg LY3502970 (Fed) |
|---|---|---|
| PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY3502970 | 1200 ± 58 | 1050 ± 40 |
PK: Tmax of LY3502970
| hour | 16 mg LY3502970 (Fasted) | 16 mg LY3502970 (Fed) |
|---|---|---|
| Time to Maximum Observed Concentration (Tmax) of LY3502970 | 8.0 (4.00 to 16.00) | 8.00 (4.00 to 24.00) |
Collected over Baseline up to Day 49. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2 Milligram (mg) LY3502970 QD | 0/33 (0%) | 0/33 (0%) | 27/33 (81.8%) |
| 4 mg LY3502970 QD | 0/30 (0%) | 0/30 (0%) | 15/30 (50%) |
| 8 mg LY3502970 QD | 0/30 (0%) | 0/30 (0%) | 13/30 (43.3%) |
| 16 mg LY3502970 QD (Fasted) | 0/28 (0%) | 0/28 (0%) | 18/28 (64.3%) |
| 16 mg LY3502970 QD (Fed) | 0/27 (0%) | 0/27 (0%) | 12/27 (44.4%) |
| Event | 2 Milligram (mg) LY3502970 QD | 4 mg LY3502970 QD | 8 mg LY3502970 QD | 16 mg LY3502970 QD (Fasted) | 16 mg LY3502970 QD (Fed) |
|---|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 18/33 | 4/30 | 2/30 | 3/28 | 1/27 |
| NauseaGastrointestinal disorders | 12/33 | 3/30 | 3/30 | 4/28 | 5/27 |
| VomitingGastrointestinal disorders | 11/33 | 4/30 | 4/30 | 2/28 | 2/27 |
| HeadacheNervous system disorders | 9/33 | 1/30 | 3/30 | 4/28 | 2/27 |
| Abdominal distensionGastrointestinal disorders | 6/33 | 2/30 | 2/30 | 4/28 | 3/27 |
| Catheter site erythemaGeneral disorders | 1/33 | 0/30 | 1/30 | 3/28 | 3/27 |
| ConstipationGastrointestinal disorders | 1/33 | 3/30 | 1/30 | 1/28 | 0/27 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/33 | 3/30 | 0/30 | 0/28 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 2/33 | 1/30 | 2/30 | 2/28 | 2/27 |
| Catheter site bruiseGeneral disorders | 0/33 | 0/30 | 0/30 | 1/28 | 2/27 |
All enrolled participants.
| Age, Continuous(years) | 2 mg/4 mg/8/ mg LY3502970 |
|---|---|
| Mean | 42.8 ± 10.2 |
| Sex: Female, Male(Participants) | 2 mg/4 mg/8/ mg LY3502970 |
|---|---|
| Female | 4 |
| Male | 30 |
| Race (NIH/OMB)(Participants) | 2 mg/4 mg/8/ mg LY3502970 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 34 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | 2 mg/4 mg/8/ mg LY3502970 |
|---|---|
| Singapore | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Feb 2022, 3 months.
Results were first posted in May 2026, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron